Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry

Clinical Chemistry

Volumn 52, Issue 6, 2006, Pages 1193-1196

  Rodríguez Cabaleiro, Diego ^a   Stöckl, Dietmar ^a   Kaufman, Jean M ^b   Fiers, Tom ^b   Thienpont, Linda M ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; PROINSULIN;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; CALIBRATION; CLINICAL ARTICLE; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ISOTOPE DILUTION ASSAY; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEASUREMENT; PANCREAS FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; STANDARDIZATION;

ADOLESCENT; ADULT; C-PEPTIDE; CHROMATOGRAPHY, LIQUID; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MIDDLE AGED; REFERENCE STANDARDS;

EID: 33646923112     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.062505     Document Type: Article

References (25)

1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21-22 October 2001 [Erratum published in: Diabetes 2004;53:1934], Diabetes 2004;53: 250-64.
2. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003;1005:362-9.
3. Greenbaum CJ, Harrison LC. Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes [Erratum published in: Diabetes 2003;52:2643]. Diabetes 2003;52:1059-65.
4. ClinicalTrials.gov. National Institute of Diabetes and Digestive and Kidney Diseases. Further research to prevent and treat type 1. Diabetes Forecast 2004;57:77-9. http://clinicaltrials.gov/ct/show/NCT00105352 (accessed February 2006).
5. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry, 3rd ed. Philadelphia: WB Saunders, 1999:750-808.
6. Marques RG, Fontaine MJ, Rogers J. C-peptide: much more than a byproduct of insulin biosynthesis [Review]. Pancreas 2004;29:231-8.
7. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-72.
8. Koskinen P. Nontransferability of C-peptide measurements with various commercial radioimmunoassay reagents. Clin Chem 1988;34:1575-8.
9. Nauck MS, Nauck MA, Nauck MA, Marz W, Wieland H. Six methods for the determination of C-peptide evaluated. Clin Chem Lab Med 1999;37:745-51.
10. Clark PM. Assays for insulin, proinsulin(s) and C-peptide [Review]. Ann Clin Biochem 1999;36:541-64.
11. Robbins DC, Tager HS, Rubenstein AH. Biologic and clinical importance of proinsulin [Review]. N Engl J Med 1984;310:1165-75.
12. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria: a prospective population-based study. Diabetes Care 1997;20:198-201.
13. Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, et al. Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset. Diabetes Care 2004;27: 1936-41.
14. United States National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Special Statutory Funding Program for Type 1 Diabetes Research: Report on Progress and Opportunities (April 2003). http://www.niddk.nih.gov/federal/planning/Jan-18-19-T1D-FINAL. pdf (accessed March 2006).
15. Stöckl D, Franzini C, Kratochvila J, Middle J, Ricos C, Thienpont LM. Current stage of standardization of measurements of specific polypeptides and proteins discussed in light of steps needed towards a comprehensive measurement system. Eur J Clin Chem Clin Biochem 1997;35:719-32.
16. Thienpont LM, Van Uytfanghe K, De Leenheer AP. Reference measurement systems in clinical chemistry [Review]. Clin Chim Acta 2002;323:73-87.
17. International Organization for Standardization. In vitro diagnostic medical devices. Measurement of quantities in samples of biological origin. Metrological traceability of values assigned to calibrators and control materials. EN/IS017511:2003. Geneva, Switzerland: ISO, 2003.
18. Roche. Instruction sheet of C-peptide Elecsys® 1010/2010/Modular Analytics E170. Mannheim, Germany: Roche Diagnostics GmbH, 2004.
19. DPC. Instruction sheet of C-peptide Immulite®. Los Angeles, CA: DPC, 2004.
20. Technogenetics (distributed by Cis Bio International). Instruction sheet of IRMA-C-PEP. Gif-Sur-Yvette Cedex, France: Cis Bio International, 2004.
21. Fierens C, Stookl D, Baetens D, De Leenheer AP, Thienpont LM. Application of a C-peptide electrospray ionization-isotope dilution-liquid chromatography-tandem mass spectrometry measurement procedure for the evaluation of five C-peptide immunoassays for urine. J Chromatogr B Analyt Technol Biomed Life Sci 2003;792:249-59
22. 2- ion of C-peptide. Rapid Commun Mass Spectrom 2004;18:3140-1.
23. Rodríguez-Cabaleiro D, Stöckl D, Thienpont LM. Improvement of sample pretreatment prior to analysis of C-peptide in serum by isotope dilution-liquid chromatography-tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:3600-2.
24. Caygill CP, Gaines Das RE, Bangham DR. Use of a common standard for comparison of insulin C-peptide measurements by different laboratories. Diabetologia 1980;18:197-204.
25. Bristow AF, Das RE. WHO international reference reagents for human proinsulin and human insulin C-peptide. J Biol Stand 1988;16:179-86.